NetApp Customers Say Hybrid Cloud is the Future of Enterprise IT in New Global Survey
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today revealed findings from its survey assessing the adoption of hybrid cloud strategies and operational focus areas among NetApp’s global enterprise customer base.
The survey of IT decision makers and infrastructure owners around the world found that 77 percent plan to operate their businesses in hybrid cloud environments for the foreseeable future in order to meet growing business demands for faster innovation, while optimizing operations and lowering infrastructure costs.
“Speed is the new scale. IT leaders everywhere are accelerating digital transformation efforts, requiring more agility and flexibility to stay ahead of their competition and deliver immediate business impact,” said Ronen Schwartz, General Manager and Senior Vice President, Cloud Volumes at NetApp. “Enterprises are embracing hybrid cloud models to effectively scale out IT resources to support business-critical applications and workloads – and NetApp is leading the industry in providing hybrid multi-cloud solutions to meet these organizations wherever they are.”
Highlights from NetApp’s 2021 Hybrid Cloud Enterprise Customer Adoption Survey include:
-
The Future is Hybrid Cloud: More than three-quarters of respondents said their organization plans to operate a hybrid cloud environment for the foreseeable future, while only 17 percent expect their organization to eventually migrate all IT to the cloud. Those surveyed listed the most important business benefits of hybrid cloud adoption to be:
- Faster Innovation - 26 percent
- Increased Responsiveness to Customers - 25 percent
- Increased Collaboration - 22 percent
- Key Operational Drivers for Hybrid Cloud Adoption: Respondents indicated they are looking to improve infrastructure flexibility and scale (27 percent), as hybrid cloud designs help IT teams get access to the on-demand and emerging technologies offered by public cloud while still leveraging legacy systems running reliably on-premises. Nearly a quarter (21 percent) said they needed to optimize costs, while 13 percent said they needed to improve data accessibility.
- Data Protection Remains Top Priority with Other Use Cases Gaining Traction: Data protection (including disaster recovery, backup and archiving) was the most popular hybrid cloud use case selected with 29 percent stating they are either utilizing hybrid cloud for data protection today or plan to within 24 months. However, customer respondents indicated they are also leveraging hybrid cloud for production use cases more than anticipated: 20 percent said they are currently integrating both on-premises and cloud resources to support the same workload for hybrid production, with 17 percent planning to do so within 24 months.
Innovative Organizations Continue to Succeed with NetApp Hybrid Cloud Solutions
The survey data shows that organizations all over the world are adopting a hybrid cloud strategy and relying on NetApp’s industry-leading solutions to accelerate their digital transformation and deliver business value faster.
“We needed the flexibility and agility of a hybrid cloud architecture to more effectively manage the massive amounts of data being generated daily across our global manufacturing facilities and development sites to accelerate time to insights and better inform decision making,” said Rohit Agrawal, Global Head of Hybrid Cloud at Siemens Healthineers. “NetApp’s hybrid cloud solutions help us streamline data center operations and keep costs under control, with the ability to centralize, manage, and secure the mission-critical data and applications.”
Methodology
The survey was conducted by NetApp among 79 organizations (54% AMER, 36% EMEA, 10% APAC) representing large and midsized organizations across diverse industries that have deployed or plan to deploy hybrid cloud architectures with NetApp.
Additional Resources
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005346/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom